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SUMMARY 
A rapid and precise homogeneous enzyme-linked competitive binding assay for riboflavin (vi- 
tamin Bz) is described. The method utilizes a malate dehydrogenase/3-carboxymethylriboflavin 
conjugate in conjunction with soluble riboflavin binding protein. In the absence of the vitamin, 
the catalytic activity of the enzyme/riboflavin conjugate is inhibited up to 71% by the binding 
protein. In the presence of riboflavin, activity is regained in an amount dependent on the ribo- 
flavin concentration. The detection limits of the dose/response curves are dependent on both the 
degree of conjugation (average number of 3-carboxymethylriboflavins per enzyme molecule) and 
the reagent ratio (conjugate/binder) used in the assay tube. Under optimized conditions, a detec- 
tion limit of 3 ng ml-’ of riboflavin can be achieved with high selectivity over other vitamins and 
biomolecules. While malate dehedrogenase activity is inhibited to some degree by components of 
human urine, use of riboflavin standards prepared in a diluted urine matrix enables the method 
to be utilized for direct determination of urinary riboflavin. 
Enzyme-linked competitive-binding assays are now used routinely in place 
of radioimmunoassay methods to detect a wide variety of biomolecules at trace 
levels [l-4]. Such methods may be classified as either heterogeneous or ho- 
mogeneous. The homogeneous types do not require time-consuming separa- 
tion of free and bound enzyme label. Indeed, analytical signals result from 
either activation or inhibition of enzyme-conjugate catalytic activity in solu- 
tion by antibody (or binding protein) interactions with the conjugate. Thus, 
homogeneous assays are simple, fast, and easily automated. 
A solid-phase enzyme-linked riboflavin assay was developed recently by uti- 
lizing a glucose-6-phosphate dehydrogenase/riboflavin conjugate in conjunc- 
tion with immobilized riboflavin-binding protein (RBP) (in place of antibody) 
[ 51. The method was shown to be quite selective and sensitive; a detection 
limit of 0.7 pmol per assay tube was achieved. However, like other heteroge- 
neous methods, the method required rather long incubation periods and tedi- 
ous separation steps. 
In this paper, the use of RBP as a reagent in enzyme-linked competitive- 
binding assays is further extended by describing a very rapid and precise ho- 
mogeneous method for the determination of riboflavin. The method utilizes a 
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malate dehydrogenase/3-carboxymethylriboflavin conjugate in conjunction 
with soluble RBP. Malate dehydrogenase (MDH) conjugates prepared in this 
study can be inhibited up to 71% in the presence of soluble RBP. These same 
conjugates ‘possess high specific activities and low degrees of ligand substitu- 
tion which enable the resulting assays to be rather sensitive. The detection 
limits of the dose-response curves are dependent on both the degree of ligand 
substitution and the reagent ratio used in the assay tube. Under optimized 
conditions, this new method is shown to offer adequate detection limits and 
selectivity for use in the direct determination of riboflavin in multivitamin 
preparations and human urine. 
EXPERIMENTAL 
Apparatus 
Enzyme activities were measured with a Gilford Stasar-III spectrophoto- 
meter equipped with a vacuum-operated sampling system and temperature- 
controlled cuvette (maintained at 30°C throughout the experiments). The 
spectrophotometer was connected to a Syva CP-5000 EMIT clinical processor 
for automatically setting the reading intervals and recording the absorbance 
values. A Syva pipetter/diluter (Model 1500) was used for delivering the con- 
jugate, binder, and substrate solutions. A Perkin-Elmer Lambda Array 3840 
photodiode array ultraviolet/visible spectrophotometer operated by a Model 
7300 Professional computer was used to record the absorption spectra of the 
enzyme, riboflavin, riboflavin analogs, and conjugates. 
Reagents 
Malate dehydrogenase (MDH) from porcine heart mitochondrial, NADH, 
oxaloacetic acid, apo-riboflavin binding protein (RBP) from chicken egg white, 
riboflavin, lumiflavin, lumichrome, flavin mononucleotide (FMN), flavin ad- 
enine dinucleotide (FAD ), as well as all other biochemicals were obtained from 
Sigma Chemical Co. and were of the highest purity available. Deionized water 
was used throughout the study. 
Activity measurements of MDH and its conjugates were made in a 0.10 M 
sodium phosphate buffer, pH 7.5, containing 0.01% (w/v) sodium azide (assay 
buffer). The dilutions of conjugates, binders, standards, and samples were made 
by using this assay buffer containing 0.10% (w/v) gelatin and 2.0 or 5.0% 
(w/v) bovine serum albumin (Tris/gel/BSA buffer). 
Preparation of MDH/3-carboxymethylribofluvin conjugates 
3-Carboxymethylriboflavin and its N-hydroxysuccinimide (NHS)-acti- 
vated ester were synthesized by using the procedure described previously [ 51. 
In order to prepare MDH/3-carboxymethylriboflavin conjugates, the required 
amount of NHS-activated 3carboxymethylriboflavin (dissolved in dimethyl 
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sulfoxide, 15 mg/200 ~1) was added to an 800~~1 aliquot of the enzyme solution 
(1250 units ml-‘, previously dialyzed against 0.10 M sodium phosphate, pH 
7.5) at 4’ C with vigorous stirring. The conjugation reaction was run for 4 h in 
the dark at 4’ C with stirring. The reaction mixture was then dialyzed against 
the assay buffer (0.10 M sodium phosphate/O.Ol% sodium azide, pH 7.5). 
Each conjugate was characterized by the degree of conjugation (average 
number of ligands per enzyme molecule), by its residual enzymatic activity, 
and by the percent inhibition induced by excess of RBP. The degree of conju- 
gation was estimated from calculations involved absorbance measurements at 
two wavelengths (225 nm and 452 nm) [ 61. A molecular weight of 70 000 was 
assumed for MDH [ 71. The residual enzymatic activity was calculated by com- 
paring the activity of a conjugated enzyme to that of a solution containing 
unconjugated enzyme of the same protein concentration. 
Procedures 
Determinations of enzymatic activity and maximum percent inhibition. The 
rate of decrease in NADH concentration, measured by the change in absor- 
bance at 340 nm per unit time, was used to determine the activity of the 
MDH/riboflavin conjugates. To determine MDH activity, 400 ~1 of a mixed 
NADH and oxaloacetic acid substrate solution (6.4 x 10m4 M NADH and 
1.9 x 10m3 M oxaloacetic acid in assay buffer) was added to a l&ml polypro- 
pylene tube (with cap) containing 200 ,ul of the conjugate solution and 400 ~1 
of Tris/gel/BSA (2% ) buffer. Both the substrate solution and the dilution of 
the conjugate were freshly prepared prior to use and kept at 0°C until the 
addition. After mixing and agitation (10 s), the reaction mixture was aspirated 
into the thermostated flow cell of the spectrophotometer. After a 20-s delay, 
absorption measurements were taken over a 1-min period (AA min-‘). 
In order to obtain data for maximum percent inhibition (Table 1) for each 
conjugate, 100 ~1 of an RBP solution (1 mg ml-‘) was substituted for 100 ~1 
of the Tris/gel/BSA buffer used above. In addition, a lo-min incubation in- 
terval preceded the addition of the substrate solution to the assay mixture. 
Association kinetic study. An RBP solution (400 ~1, 15.6 lug ml-‘) in 
Tris/gel/BSA buffer was incubated for varying periods of time with 200 ~1 of 
7.1~10~’ M conjugate (conj-14) in the same buffer. After each incubation 
period, 400 ~1 of the substrate solution was added and the enzymatic activity 
was determined as described above. 
Binding-protein dilution curves. Portions (400 ~1) of solutions containing 
different amounts of RBP were incubated with 200~1 of 7.1 x lo-’ M conjugate 
(conj-12, conj-14, and conj-17) for 15 min. The substrates were then added 
and the enzymatic activity was measured as above. A binder dilution curve was 
prepared by plotting percent inhibition vs. amount of RBP added. 
Dose/response curves. Standard solutions of each flavin (riboflavin, lumi- 
flavin, lumichrome, FMN, and FAD) were prepared as described previously 
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TABLE 1 
Parameters of MDH/3-carboxymethylrboflavin conjugates 










































*Refers to molar ratios of NHS-activated 3-carboxymethylribofavin to MDH in the conjugation 
reaction. bFor all conjugates, a fixed amount of protein (MDH) was incubated with a fixed amount 
of RBP. 
[ 51 except that Tris/gel/BSA buffer was used to dilute each stock solution. In 
the homogeneous assay protocol, 200 ,uI of a standard solution and 200 ~1 of a 
conjugate solution were sequentially added to an assay tube containing 200 ~1 
of an RBP solution and the mixture was incubated for 15 min at room tem- 
perature. The resulting enzymatic activity was measured as outlined above 
Dose/response curves were constructed by plotting percent inhibition or ab- 
sorbance change dA min- ’ at 340 nm vs. logarithm of the flavin concentration 
in the standards. 
Determination of riboflavin in multivitamin preparations. The contents of 
7-50 capsules or tablets of commercial multivitamin preparations were weighed, 
powdered, and mixed. A quantity of each powdered mixture (15-40 mg) was 
then weighed and dissolved in 2 1 of phosphate buffer. From this sample solu- 
tion, further dilutions in Tris/gel/BSA (2% ) buffer were prepared and stored 
in the dark at 4°C. These samples were processed (as soon as possible) ac- 
cording to the homogeneous assay protocol described above. The unknown 
concentrations were estimated graphically from the calibration curve. Only the 
steep portion of the dose/response curve was used for analytical purposes. The 
same samples were also assayed for riboflavin by a fluorescence titration 
method, following the procedure described by Tillotson and Bashor [ 81. 
Urine analysis . Twenty-two random urine samples were collected and frozen 
in the dark until assayed. A riboflavin-free urine pool was prepared by incu- 
bating numerous urine samples with an excess quantity of high coverage RBP 
beads (RBP immobilized on Sepharose, prepared as described earlier [ 5 ] ) to 
remove riboflavin. This urine pool was then diluted 1: 10, 1: 20, or 1: 40 with 
Tris/gel/BSA (5% ) buffer and used for the preparation of the standard ribo- 
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flavin solutions (urine-based standards). The unknown urine samples were 
diluted 1: 10,l: 20, or 1: 40 with the same buffer and analyzed according to the 
homogeneous assay protocol. For the urine assays, both the RBP and conjugate 
solutions were prepared with Tris/gel/BSA (5% ) buffer. The amount of uri- 
nary riboflavin in the unknown samples was graphically determined from the 
corresponding calibration curve (i.e., standard solutions prepared with a urine 
pool diluted as much as the urine samples). 
RESULTS AND DISCUSSION 
During the development of a solid-phase (heterogeneous) enzyme-linked 
riboflavin assay with immobilized RBP [ 51, it was observed that even highly 
substituted glucose-g-phosphate dehydrogenase (GGPDH) /riboflavin conju- 
gates with degrees of conjugation up to 26.7 could not be inhibited to a signif- 
icant degree by excess of soluble RBP (i.e., 21% inhibition). This was somewhat 
surprising because previously it was shown that GGPDH/vitamin B12, 
GGPDH/folate, and GGPDH/biotin conjugates could be inhibited to a much 
greater extent by corresponding natural binders [g-11 1. While low homoge- 
neous inhibition of conjugates is actually preferred for the heterogeneous ar- 
rangements, weakly inhibited riboflavin/enzyme conjugates are not suitable 
for the development of a sensitive homogeneous assay system. 
In subsequent work, it was found that malate dehydrogenase, when cova- 
lently linked to the 3-carboxymethylriboflavin derivative in the same manner 
used to prepare earlier GGPDH/riboflavin conjugates, could be inhibited up to 
71% in the presence of excess of RBP. Consequently, MDH was chosen as a 
labeling enzyme for the development of the new homogeneous riboflavin assay. 
Malate dehydrogenase has been used previously in homogeneous enzymatic 
immunoassays for morphine [ 121, thyroxine [ 13,141, and tetrahydrocanna- 
binol [ 151. This highly stable enzyme is readily detectable at levels approach- 
ing lo-l1 M during a 1-min measurement and is available in high purity. 
N( 3 ) -carboxymethylriboflavin was attached to the enzyme through its free 
carboxyl group to prepare all MDH/riboflavin conjugates used in this study. 
Numerous MDH/3-carboxymethylriboflavin conjugates were synthesized by 
using different initial ligand/enzyme ratios. The conjugation reaction was done 
without protecting the active site of the enzyme because, as suggested by Row- 
ley et al. [ 121, conjugation of this enzyme in the presence of substrates could 
yield conjugates which cannot be inhibited. Table 1 summarizes the charac- 
teristics of the resulting conjugates. Attempts to prepare highly substituted 
conjugates (e.g., 250 : 1 or 500 : 1 initial riboflavin/enzyme ratios) led to insol- 
uble products. With increasing substitution, the residual enzyme activity at 
first dropped off rapidly and then gradually leveled off (Table 1) . However, 
the percent inhibition by excess of RBP did not increase proportionally with 
the degree of conjugation (Table 1). Indeed, a maximum value of 71.4% inhi- 
36 
0 6 12 18 24 30 0 2 4 6 
incubation Time (min) Alno”” “l REP (pg) 
Fig. 1. Rate of association between malate dehydrogenase/riboflavin conjugate (7.1 X 10e9 M conj- 
14) and RBP (15.6 pg ml-‘). Data points are means of quintuple measurements. 
Fig. 2. Binding-protein dilution curves obtained by incubating varying amounts of RBP with the 
same concentration (7.1 x lo-’ M) of three different conjugates: (A) conj-14; (B) conj-17; (C) 
conj-12. The x-axis refers to amount of RBP in the assay tubes. Means of duplicate measurements 
are plotted. 
bition was achieved with 5.2 riboflavin residues per enzyme molecule. Inhibi- 
tion induced by RBP then decreases with further riboflavin substitution. 
Prior to evaluating the analytical utility of the conjugates, the kinetics of 
the association between the enzyme/riboflavin conjugates and RBP was stud- 
ied in an effort to determine an optimal incubation time for the assay. An 
extremely fast association (see Fig. 1) was observed. This was expected based 
on the known association rate constants, on the order of 107-lo* M-’ s-l, for 
RBP toward flavin analogs [ 161. As shown in Fig. 1, > 90% of the maximum 
inhibition was achieved within 5 min of incubation. However, in all subsequent 
studies, an incubation period of lo-15 min was used to gain a nearly maximum 
change in signal for the method. 
A binding-protein dilution curve can be used to determine the reagent con- 
centrations (both conjugate and RBP ) required in an assay tube to obtain a 
desired signal change (enzyme activity and/or % inhibition). It can also be 
utilized to determine the optimum concentration of binder to be used in ho- 
mogeneous enzyme-linked competitive binding assays. For example, Kabakoff 
and Greenwood [ 171 suggested that the amount of binder that corresponds to 
85% of the maximum homogeneous inhibition will result in a dose/response 
curve with optimized detection capabilities. Thus, for these purposes, three 
binding-protein dilution curves (Fig. 2) were constructed by using the same 
molar concentration of three different conjugates (conj-12, conj-14, and conj- 
17 ). Surprisingly, despite the differing degrees of substitution, the maximum 
inhibition for each conjugate was reached at approximately the same concen- 
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Fig. 3. The effect of various RBP concentrations on the dose/response curve for riboflavin. The 
concentration of conj-14 was fixed at 7.1 X lo-’ M. The amounts (pug) of RBP in the assay tubes 
were: (A) 3.12; (B) 1.56; (C) 0.78; (D) 0.39; (E) 0.20. Data points are means of duplicate 
measurements. 
Fig. 4. Typical calibration curve for riboflavin also showing the f 1 standard deviation (prepared 
by using the same reagent concentrations as for curve C in Fig. 3 ). Quintuple measurements were 
used for calculating the standard deviation. 
to sites associated with RBP-induced inhibition to the total riboflavin residues 
in each conjugate is approximately the same, regardless of the degree of sub- 
stitution of the enzyme. All subsequent analytical studies were done with conj- 
14. 
Several dose/response curves (Fig. 3 ) were constructed by varying the RBP 
concentration with a fixed amount of conj-14. Decreasing the binder concen- 
tration shifts the dose/response curves to lower detection ranges. However, 
this occurred at the expense of decreasing the extent of both the steepness and 
the maximum percent inhibition of the dose/response curve. It was previously 
reported that extremely steep curves (curves A-D ) can occur when the binder 
shows a higher association constant toward the free analyte than the enzyme- 
labeled analyte [ 181. Indeed, the association constant of RBP toward 3-car- 
boxymethylriboflavin (7.1 x lo7 M-l) [ 191, used to prepare the conjugates in 
this study, is a decade lower than the association constant of riboflavin (7.8 x lOa 
M-’ [ 161) and might be further reduced upon attachment to a bulky enzyme. 
In order to evaluate the precision of the proposed method, the reagent ratio 
which yielded curve C in Fig. 3 was arbitrarily chosen and a new calibration 
curve was prepared along with the t 1 standard deviation (n= 5) for each 
point (Fig. 4). An average standard deviation of ? 1.9 x 10V3 dA min-l (range 
of 0.8~10-~-3.0~10-~), or an average relative standard deviation of 1.2%, 
was obtained for the entire riboflavin concentration range tested. The relative 
precision in terms of riboflavin concentration, however, is also dependent on 
the steepness of a curve and will decrease dramatically in regions where the 
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Fig. 5. Dose/response curves for riboflavin and riboflavin analogs; (A) riboflavin; (B) lumiflavin; 
(C) FMN; (D) lumichrome; (E) FAD. The points on the curves are means of duplicate 
measurements. 
calibration curve flattens. Near the midpoint of the curve shown in Fig. 5, the 
average standard deviation ( IL 1.9 x low3 dA min-’ ) corresponds to 2 3.0% 
uncertainty in riboflavin concentrations. 
The cross-reactivity of the method to several structurally related flavin an- 
alogs (lumiflavin, lumichrome, FMN, and FAD) was examined (Table 2) by 
using the reagent ratio which resulted in curve C (Fig. 3) for riboflavin stan- 
TABLE 2 
Flavin cross-reactivities of competitive binding assays 
Flavin Cross-reactivity” (enzyme-linked) 
(%) 




Riboflavin 100 100 100 7.8 x 10’ 
Lumiflavin 13.6 7.3 8.0 2.1 x 101 
Lumichrome 1.2 1.3 1.1x107 
FMN 7.6 9.3 27.5 7.3 x 105 
FAD 0.3 0.4 4.0 < 7.0 x lo4 
“Determined by dividing the concentration of riboflavin at 50% of the maximum response, by the 
concentration of analog that yields 50% of the maximum response. bFrom [5]. “From [20]. 
dDetermined by fluorescence titration (from [ 161). 
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Fig. 6. Typical calibration curves obtained by using riboflavin standards prepared in a 1: 10 dilu- 
tion (curve C) and a 1:20 dilution (curve B) of a riboflavin-free urine pool. For comparison 
purposes, curve A is that obtained with normal aqueous riboflavin standards. All data were ob- 
tained by using the same reagent concentrations as for curve C in Fig. 3. Data points are means 
of triplicate measurements. 
Fig. 7. Correlation of the homogeneous and the heterogeneous methods for the determination of 
riboflavin in human urine. 
dards. Figure 5 illustrates the dose/response of the homogeneous assay to these 
analogs. For the most part, the cross-reactivity observed was as expected based 
on known association constants of these analogs toward RBP (Table 2). How- 
ever, a much higher cross-reactivity than expected was observed for FMN. As 
can be seen (Fig. 6 and Table 2), the cross-reactivity for FMN (curve C) was 
similar to the cross-reactivity for lumiflavin (curve B), while the association 
constant for FMN (7.3 x lo5 M-l) is known to be much lower than that for 
lumiflavin (2.1 x lo7 M-’ ) (association constants determined by fluorescence 
titration [ 161). This strange observation has been reported previously, both 
in an earlier solid-phase riboflavin assay [5] as well as in an RBP-based ra- 
dioassay for riboflavin developed by Fazekas et al. [ 201. 
The high selectivity of the proposed method, over a wide range of other vi- 
tamins, was demonstrated by determining the riboflavin content of various 
commercial multivitamin preparations (Table 3). The new method requires 
only a simple dilution of the original sample. Results obtained by the present 
method were consistent with those determined by the fluorimetric titration 
method [8] and were in good agreement with the manufacturers’ claims. 
Preliminary studies were also undertaken to test the feasibility of using the 
method for the measurement of urinary riboflavin. However, it was found that 
both native and conjugates of MDH were significantly inhibited by compo- 
nents in urine. For example, the percent inhibition caused by twenty random 
urine samples (which were diluted 1: 2 with Tris/gel/BSA (5% ) buffer), ranged 
from 35.8% to 49.5% with an average t s.d. of 43.2 + 5.6%. Subsequent exper- 
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TABLE 3 
Results for determination of riboflavin in multivitamin preparations 












Vitamin B complex 
Vitamin B complex 
Vitamin B complex and 
vitamin C 
Vitamin B complex and 
vitamin C 
Multiple vitamin (A, 
D, E, C and B- 
complex) and minerals 
6 6.12?0.09 6.16 
50 52.1 f 2.2 53.7 
5 5.57kO.12 5.49 
50 49.7 I! 1.0 48.3 
25 20.7 f 0.7 20.8 
“Reported as a mean of ten determinations f standard deviation. bReported as a mean of two 
determinations by the method of Tillotson and Bashor [ 81. 
iments revealed that more diluted urine causes less inhibition (i.e., 11.6 + 1.8% 
with 1: 10 dilution and 6.8 2 1.2% with 1: 20 dilution using the same twenty 
urine samples). As can be seen, variations in percent inhibition between urine 
samples were greatly reduced by such dilutions, Thus, at least 1: 10 diluted 
urine samples were used for all determinations. Further to improve the accu- 
racy of the measurements in urine, the standards were prepared from a ribo- 
flavin-free urine pool. Figure 6 shows the calibration curves obtained by using 
a 1: 10 (curve C ) and 1: 20 (curve B ) diluted urine pool, respectively, along 
with the normal calibration curve A (non-urine based). By using the calibra- 
tion curves prepared with urine-based standards, the riboflavin content of 22 
random urine samples was determined. The results obtained (average 
value= 1280 ng ml-‘; range= 184-4171 ng ml-‘) coincided well with the nor- 
mal ranges reported by others [8,20]. The same urine samples were analyzed 
by the earlier heterogeneous assay protocol [ 51 and the data obtained by two 
methods (homogeneous and heterogeneous) correlated quite well (Fig. 7) 
(correlation coefficient = 0.990; slope = 1.01). While the urine-based calibra- 
tion method proposed above appears to be reliable, it should be realized that 
the approach increases the overall detection limits of the homogeneous assay 
(lo-fold for the urinary riboflavin determination). However, this is not a sig- 
nificant problem given the normal ranges of riboflavin in urine and the abso- 
lute detection capabilities of the new method. It should further be noted that 
the problem of unknown urine components inhibiting MDH activity may be 
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the reason that previous homogeneous enzymatic immunoassays based on 
MDH also use urine-based standards for calibration purposes [ 151. 
In summary, a simple homogeneous assay for riboflavin has been devised. 
The proposed method is faster than the corresponding heterogeneous enzyme- 
linked method and most other existing methods. The method can readily de- 
tect as little as 3 ng ml-’ (8 nM) of riboflavin (or 30 ng ml-’ for urine sam- 
ples) with excellent precision. In view of the potential for full automation of 
homogeneous assays, it is believed that the method described here will offer an 
attractive practical alternative for the routine measurement of riboflavin in a 
variety of samples. 
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boflavin in urine samples. This work was supported under Grant CHE-8506695 


















D. Monroe, Anal. Chem., 56 (1984) 920A. 
A. Voller and D.E. Bidwell, in W.P. Collins (Ed.), Alternative Immunoassay, Wiley, New 
York, 1985, p. 77. 
E.T. Maggio (Ed.), Enzyme-Immunoassay, CRC Press, Baco Raton, FL, 1980. 
M. Oellerich, J. Clin. Chem. Clin. Biochem., 18 (1980) 197. 
G.S. Cha and M.E. Meyerhoff, Anal. Biochem., 168 (1988) 216. 
K.L. Cheng, in J.D. Winefordner (Ed.), Spectrochemical Methods of Analysis, Vol. 9, Wiley- 
Interscience, New York, 1971, p. 321. 
C.J.R. Thorne and N.O. Kaplan, J. Biol. Chem., 238 (1963) 1861. 
J.A. Tillotson and M.M. Bashor, Anal. Biochem., 107 (1980) 214. 
C.D. Tsalta and M.E. Meyerhoff, Anal. Chem., 59 (1987) 837. 
L.G. Bachas and M.E. Meyerhoff, Anal. Chem., 58 (1986) 956. 
C.D. Tsalta, L.G. Bachas, S. Daunert and M.E. Meyerhoff, BioTechniques, 5 (1987) 148. 
G.L. Rowley, K.E. Rubenstein, J. Huisjen and E.F. Ullman, J. Biol. Chem., 250 (1975) 3759. 
E.F. Ullman, J. Blakemore, R.K. Leute, W. Eimstad and A. Jaklitsch, Clin. Chem., 21 (1975) 
1011. 
E.F. Ullman, R. Yoshida, J. Blakemore, E.T. Maggio and R.K. Leute, Biochim. Biophys. 
Acta, 567 (1979) 66. 
R. Rodgers, C.P. Crowl, W.M. Eimstad, M.W. Hu, J.K. Kam, R.C. Ronald, G.L. Rowley and 
E.F. Ullman, Clin. Chem., 24 (1978) 95. 
J. Bevcar, Ph.D. Dissertation, University of Michigan, 1973. 
D.S. Kabakoff and H.M. Greenwood, in K.G.M. Alberti and C.P. Price (Eds.), Recent Ad- 
vances in Clinical Biochemistry, Vol. 2, Livingston C, London, 1981, p. 1. 
L.G. Bachas and M.E. Meyerhoff, Anal. Biochem., 156 (1986) 223. 
J.D. Choi and D.B. McCormick, Arch. Biochem. Biophys., 204 (1980) 41. 
A.G. Fazekas, C.E. Menendex and R.S. Rivlin, Biochem. Med., 9 (1974) 167. 
